Effects of Spironolactone on Matrix Metalloproteinases (MMPs) in Heart Failure

Effects of Spironolactone on Circulating MMPs in Patients With Chronic Heart Failure

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00663195

Enrollment

Registered

2008-04-22

Start date

2004-01-31

Completion date

2005-12-31

Last updated

2008-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Stable Heart Failure

Keywords

heart failure, fibrosis, MMP, spironolactone, furosemide

Brief summary

The purpose of this study is to evaluate the effects of spironolactone on circulating MMP levels and insulin resistance in patients with chronic heart failure.

Detailed description

Myocardial fibrosis is observed in failing hearts. MMPs are considered markers of fibrosis. Recently, circulating MMPs can be measured and are elevated in patients with chronic heart failure (CHF). It has been reported that spironolactone improves myocardial fibrosis in CHF animal models. Therefore, the purpose of this study is to evaluate the effects of spironolactone on circulating MMP levels in patients with chronic heart failure.

Interventions

DRUGspironolactone + furosemide

spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16 weeks

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Inclusion criteria

* chronic stable heart failure

Design outcomes

Primary

Measure	Time frame
MMP levels	16 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026